Continuous Tralokinumab Treatment over 4 Years in Adults with Moderate-to-Severe Atopic Dermatitis Provides Long-Term Disease Control. (2024). SKIN The Journal of Cutaneous Medicine, 8(2), s376. https://doi.org/10.25251/skin.8.supp.376